As we usher in 2025, it’s the perfect time to prioritize health and wellness. Registered Dietitian and Nutritionist Kelly ...
Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...
In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.
Mit Blick auf die Neuausrichtung der Medikamentenpipeline von Bayer hatte Pharma-Chef Stefan Oelrich im letzten Januar ...
Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...
Bayer's projected earnings decline and litigation pressures affect its outlook. Find out why BAYRY stock might face ...
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...